FY2026 Earnings Estimate for Biogen Issued By HSBC

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at HSBC issued their FY2026 earnings estimates for shares of Biogen in a research note issued on Friday, April 17th. HSBC analyst M. Herholdt forecasts that the biotechnology company will post earnings of $16.06 per share for the year. HSBC has a “Reduce” rating and a $150.00 price objective on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.70 per share. HSBC also issued estimates for Biogen’s FY2027 earnings at $16.26 EPS, FY2028 earnings at $16.67 EPS and FY2029 earnings at $16.23 EPS.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Several other research firms also recently weighed in on BIIB. Stifel Nicolaus boosted their target price on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. BMO Capital Markets boosted their target price on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Barclays began coverage on shares of Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price on the stock. Oppenheimer lifted their price objective on shares of Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $209.77.

Biogen Stock Up 1.4%

NASDAQ:BIIB opened at $185.95 on Wednesday. The company has a market cap of $27.29 billion, a PE ratio of 21.11, a P/E/G ratio of 2.46 and a beta of 0.16. Biogen has a twelve month low of $115.25 and a twelve month high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company’s 50 day moving average is $185.55 and its two-hundred day moving average is $174.62.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Institutional investors and hedge funds have recently modified their holdings of the stock. Convergence Investment Partners LLC acquired a new position in shares of Biogen in the 3rd quarter worth approximately $1,342,000. Caprock Group LLC acquired a new position in shares of Biogen in the 3rd quarter worth approximately $742,000. Leuthold Group LLC acquired a new position in shares of Biogen in the 3rd quarter worth approximately $3,294,000. Generali Investments Management Co LLC lifted its holdings in shares of Biogen by 408.2% in the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after acquiring an additional 8,008 shares during the last quarter. Finally, CWM LLC lifted its holdings in shares of Biogen by 36.4% in the 3rd quarter. CWM LLC now owns 47,455 shares of the biotechnology company’s stock worth $6,648,000 after acquiring an additional 12,673 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo upgraded BIIB to Overweight and lifted its price target to $250, citing renewed confidence in Biogen’s growth runway (notably Alzheimer’s franchise momentum and pipeline optionality). Wells Fargo Upgrade
• Positive Sentiment: UBS upgraded BIIB to Buy with a $225 target, arguing Biogen’s late‑stage pipeline, the recent Apellis acquisition background, and a valuation gap support 25–50% upside. UBS Upgrade
• Positive Sentiment: Biogen agreed to acquire exclusive Greater China rights to felzartamab (payable up to $850M), consolidating worldwide rights as the antibody advances in Phase 3 trials — a de‑risking move that expands potential commercial opportunity in immune‑mediated diseases. Felzartamab China Deal (Reuters)
• Neutral Sentiment: Investors should watch the upcoming quarterly results and management commentary — previews expect modest near‑term EPS movement but emphasize pipeline updates and guidance as the next catalysts. Earnings Preview
• Neutral Sentiment: Recent earnings call/transcript material is circulating (Q2/Q3 filings/transcripts available) that investors may parse for R&D spend, launch cadence and pipeline timeline details. Earnings Transcript
• Negative Sentiment: HSBC reiterated a “Reduce” rating with a $150 price target and published lower quarterly/annual EPS estimates, a reminder that some analysts view Biogen as richly valued versus remaining execution risks. HSBC Estimates / Reduce
• Negative Sentiment: Opinion pieces arguing to avoid BIIB highlight valuation after recent gains and potential binary clinical/commercial risks — these views can pressure sentiment if upcoming results or pipeline readouts disappoint. 3 Reasons to Avoid BIIB

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.